Skip to content
Back to PMN

ProMIS Neurosciences Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
11
Purchases
11
Sales
0
Purchase value
$8.88M
Sale value
$0.00

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Eugene WilliamsDirector
4
Filed Nov 6, 2026Period of report Nov 4, 20260001374339-26-000011
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseNov 4, 2026
Common Shares26,500$3.43$90.90K40,213Direct
Open on SEC EDGAR
Neil CashmanDirector · Chief Scientific Officer
4
Filed Nov 3, 2026Period of report Nov 2, 20260001374339-26-000009
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseNov 2, 2026
Common Shares10,000$3.86$38.60K14,532Direct
Open on SEC EDGAR
Eugene WilliamsDirector
4
Filed Nov 3, 2026Period of report Oct 30, 20260001374339-26-000010
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseOct 30, 2026
Common Shares1,316$3.99$5.25K13,713Direct
Open on SEC EDGAR
Johanne KaplanChief Development Officer
4
Filed Aug 7, 2026Period of report Aug 5, 20260001104659-26-092673
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseAug 5, 2026
Common Shares2,280$13.30$30.32K6,221Direct
Open on SEC EDGAR
Patrick D. KirwinDirector
4
Filed Apr 23, 2026Period of report Apr 22, 20260001104659-26-047977
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseApr 22, 2026
Common Shares4,000$11.33$45.32K4,653IndirectBy Patrick D. Kirwin Professional Corp
Open on SEC EDGAR
Eugene WilliamsDirector
4
Filed Mar 6, 2026Period of report Mar 5, 20260001374339-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMar 5, 2026
Common Shares2,000$24.40$48.80K12,397Direct
Open on SEC EDGAR
Eugene WilliamsDirector
4
Filed Mar 4, 2026Period of report Mar 2, 20260001374339-26-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMar 4, 2026
Common Shares2,000$24.00$48.00K10,397Direct
PurchaseMar 3, 2026
Common Shares1,000$21.89$21.89K8,397Direct
PurchaseMar 2, 2026
Common Shares1,000$22.53$22.53K7,397Direct
Open on SEC EDGAR
Johanne KaplanChief Development Officer
4
Filed Feb 23, 2026Period of report Feb 19, 20260001374339-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseFeb 19, 2026
Common Shares1,629$15.35$25.01K3,941Direct
Open on SEC EDGAR
ABG Management Ltd.10% owner
Slanix Paul AlexDirector
Ally Bridge Group (NY) LLC10% owner
Ally Bridge MedAlpha Master Fund L.P.10% owner
Yu Fan10% owner
4
Filed Feb 5, 2026Period of report Feb 3, 20260001493152-26-005410
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseFeb 3, 2026
Common SharesF1F2F3F4F5700,741$12.13$8.50M943,090IndirectSee Footnote
Filing footnotes · 7
  1. F1The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of $12.13 per Common Share.
  2. F2The Common Shares reported herein include: (i) 407,230 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) 206,100 Common Shares held of record by ABG V-SIV X Limited.
  3. F3Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P.
  4. F4Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited.
  5. F5Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited.
  6. F6The warrants to purchase Common Shares (the "Warrants") are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the "Milestone Event" means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310.
  7. F7The Warrants reported herein include: (i) Warrants to purchase 164,881 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) Warrants to purchase 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) Warrants to purchase 206,100 Common Shares held of record by ABG V-SIV X Limited.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.